Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
May 13, 2024 04:00 ET | Macomics Limited
Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophagesThe...
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
October 19, 2023 04:00 ET | Macomics Limited
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent...
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 08:00 ET | Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company...
Myricx Enters into Antibody License Agreement with Biocytogen
September 07, 2023 07:00 ET | Myricx Bio
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
April 17, 2023 13:30 ET | Macomics Limited
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its...
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
April 17, 2023 13:30 ET | Myricx Pharma
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload...
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
March 23, 2023 02:00 ET | Macomics Limited
Worldwide drug discovery collaboration agreement with Ono to develop new antibody drugs against a novel macrophage target of interest in immuno-oncologyMacomics will develop antibody candidates...
Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments
February 17, 2023 05:19 ET | Macomics Limited
Publication in Nature Reviews Cancer based on data gained over 50 years of discovery research in the area of macrophage biologyReveals future prospects for developing precision medicines to modulate...
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
October 05, 2022 08:00 ET | Codiak BioSciences, Inc.
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting – CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
June 29, 2022 08:00 ET | Codiak BioSciences, Inc.
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak...